Ildong Pharmaceutical announced on June 11 that it has signed a memorandum of understanding (MOU) with digital healthcare company Welt to jointly develop and commercialize AI-based digital therapeutics.
The agreement aims to combine Ildong's pharmaceutical and health supplement portfolio with Welt's AI agent platform, DrugOS, to enhance medication adherence and treatment outcomes through digital therapeutics.
DrugOS is a platform that supports medication timing management, adverse reaction monitoring, and prediction of treatment discontinuation risks, allowing for interaction with patients to manage their treatment processes. It operates based on the digital guidelines for prescription drug use established by the U.S. Food and Drug Administration (FDA) and the domestic digital medical product regulations.
The two companies plan to accumulate real-world evidence (RWE) and validate improvements in medication adherence and treatment efficacy in response to the implementation of the digital medical product law and the introduction of digital therapeutic guidelines in the second half of this year.
Initially, they will apply DrugOS to over-the-counter medications and health supplements, such as the Aranamin series, to validate the market and gather data. They intend to expand the application to prescription drugs and new or improved medications in the future.
Additionally, they will gradually apply the platform to key product lines, enhancing the existing portfolio into AI-based digital therapeutics through joint development. Ildong Pharmaceutical will handle commercialization and regulatory compliance, while Welt will manage platform operations and data analysis. They also plan to pursue joint licensing opportunities with global pharmaceutical companies based on the RWE and clinical evidence obtained in South Korea.
Welt established a foundation for global expansion by signing a partnership with the German Digital Health Association in 2024, becoming the first Asian company to do so, and setting up a local office in Munich. Last year, it obtained CE certification, which meets European medical device regulatory requirements, and ISO 27001, an international standard for information security management systems.
Yoon Woong-seob, CEO of Ildong Pharmaceutical, stated, "The integration of pharmaceuticals and digital technology will create a new paradigm that improves patient treatment experiences and outcomes beyond just medication reminder services. Through our collaboration with Welt, we aim to provide differentiated value to users and lead the digital therapeutics market."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.